1. Jiang J, Luo L, Zhang Z*, Liu X, Chen N, Li Y, Sheng L*. The Active Glucuronide Metabolite of the Brain Protectant IMM-H004 with Poor Blood-Brain Barrier Permeability Demonstrates a High Partition in the Rat Brain via Multiple Mechanisms. Pharmaceutics. 2024;16(3):330.
2. Zhang Y, Deng J, Tian H, Qi H, Xiong T, Lin S, Dong Y, Luo L, Wu D, Zhang K, Ji M, Du T, Sheng L*, Chen X*, Xu H*. Design, Synthesis, and Bioevaluation of Novel Reversibly Photoswitchable PI3K Inhibitors Based on Phenylazopyridine Derivatives toward Light-Controlled Cancer Treatment. J Med Chem. 2024;67(5):3504-3519.
3. Zhou J, Wang W, Liu D, Xu S, Wang X, Zhang X, Wang X, Li Y, Sheng L*, Wang X*, Xu B*. Discovery of 2-Ethoxy-5-isobutyramido-N-1-substituted Benzamide Derivatives as Selective Kv2.1 Inhibitors with In Vivo Neuroprotective Effects. J Med Chem. 2024;67(1):213-233.
4. Luo LJ, Liu X, Li Y, Li Y, Sheng L*. Characterization of the metabolic contributions of cytochrome P450 isoforms to bicyclol using the relative activity factor method. J Asian Nat Prod Res. 2024:1-12.
5. Li Z, Zhang X, Wu H, Ma Z, Liu X, Ma J, Zhang D, Sheng L*, Chen X*, Zhang S*. Hydrangea paniculata coumarins attenuate experimental membranous nephritis by bidirectional interactions with the gut microbiota. Commun Biol. 2023;6(1):1189.
6. Zhou J, Du T, Wang X, Yao H, Deng J, Li Y, Chen X, Sheng L*, Ji M, Xu B. Discovery of Quinazoline-2,4(1H,3H)-dione Derivatives Containing a Piperizinone Moiety as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis. J Med Chem. 2023;66(20):14095-14115.
7. Luo L, Liu X, Jin X, Liu Y, Ma J, Zhang S, Zhang D, Chen X, Sheng L*, Li Y. Simultaneous determination of skimmin, apiosylskimmin, 7-hydroxycoumarin and 7-hydroxycoumarin glucuronide in rat plasma by liquid chromatography-Orbitrap mass spectrometry and its application to pharmacokinetics. Biomed Chromatogr. 2022;36(1):e5223.
8. Luo L, Chang Y, Sheng L*. Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective. Life Sci. 2023;321:121614.
9. Weida Wang#, Li Sheng#, Yuanyuan Chen, Zhaojun Li, Haijie Wu, Jie Ma, Dongming Zhang, Xiaoguang Chen*, Sen Zhang*.(2021) Total coumarin derivates from Hydrangea paniculata attenuate renal injuries in cationized-BSA induced membranous nephropathy by inhibiting complement activation and interleukin 10-mediated interstitial fibrosis. Phytomedicine doi.org/10.1016/j.phymed.2021.153886.
10. Zhao H#, Gao Y#, Li W#, Sheng L#, Cui K, Wang B, Fu L, Gao M, Lin Z, Zou X, Jackson M, Huang H*, Lu Y*, Zhang D*. (2022) Design, Synthesis, and Biological Evaluation of Pyrrole-2-carboxamide Derivatives as Mycobacterial Membrane Protein Large 3 Inhibitors for Treating Drug-Resistant Tuberculosis. J Med Chem. 2022 Aug 11;65(15):10534-10553.
11. Li S, Liao H, Luo L, Meng B, Zheng F, Sheng L, Zhao H, Huan Y, Lei L, Zhai J, Zhao K, Tian J, Wu T, Li G, Pang J, Huang H. Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities. Eur J Med Chem. 2024;269:116327.
12. Kong L, Zhao Q, Jiang X, Hu J, Jiang Q, Sheng L, Peng X, Wang S, Chen Y, Wan Y, Hou S, Liu X, Ma C, Li Y, Quan L, Chen L, Cui B, Li P. Trimethylamine N-oxide impairs β-cell function and glucose tolerance. Nat Commun. 2024;15(1):2526.
13. Ding W, Yan L, Sheng L, Chen S, Li Y, Cheng S, Luo L, Huang H, Shao H, Zhang D. Identification of Piperazinyl-Difluoro-indene Derivatives Containing Pyridyl Groups as Potent FGFR Inhibitors against FGFR Mutant Tumor: Design, Synthesis, and Biological Evaluation. J Med Chem. 2024;67(4):2941-2962.
14. Zhang K, Huang R, Ji M, Lin S, Lai F, Wu D, Tian H, Bi J, Peng S, Hu J, Sheng L, Li Y, Chen X, Xu H. Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia. Eur J Med Chem. 2024;264:116015.
15. Xia L, Jiang L, Du T, Lin S, Xiong T, Peng S, Tian H, Zhang K, Wu D, Sheng L, Ji M, Chen X, Xu H. Design, synthesis, and biological evaluation of novel bivalent PI3K inhibitors for the potential treatment of cancer. Bioorg Chem. 2023;140:106814.
16. Lin S, Du T, Zhang J, Wu D, Tian H, Zhang K, Jiang L, Lu D, Sheng L, Li Y, Ji M, Chen X, Xu H. Optimization of Benzamide Derivatives as Potent and Orally Active Tubulin Inhibitors Targeting the Colchicine Binding Site. J Med Chem. 2022;65(24):16372-16391.
17. Du T, Zhang Z, Zhou J, Sheng L, Yao H, Ji M, Xu B, Chen X. A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers. Front Pharmacol. 2022;13:865085.